CME Portal
CME Certificate and Information
Online Education
AVAHO Learning Center (LMS)
ONGOING OPPORTUNITIES
These educational resources are provided to you through partnerships with other educational organizations and are not AVAHO-developed education.
A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives
CME | 1.00 Credit
Time to Complete: 1 hour
Released: December 20, 2024
Expires: December 19, 2025
Maximum Credits:
1.00 / AMA PRA Category 1 Credit(s)™
1.00 / NCPD Contact Hour
1.00 / CPE Contact Hour (0.10 CEU)
1.00 / AAPA Category 1 CME Credits
Learning Objectives:
- Utilize patient needs and preferences to evaluate potential unmet needs of patients with hemophilia
- Compare the clinical profiles of novel and emerging therapies for hemophilia
- Assess how new and emerging treatments impact the individualization of treatment for patients with hemophilia
Course Description:
Discover the impact of cutting-edge therapies reshaping hemophilia care! From groundbreaking innovations to real-world patient perspectives, this activity brings together leading hemophilia specialists, a dedicated community-based physician, an experienced hemophilia nurse, and a patient with lived experience to share their unique insights.
Provided by The France Foundation
New Therapies Across the Spectrum of Prostate Cancer: What do Urology Nurses and Advanced Practice Providers Need to Know?
CME | CNE | CPE | 1.00 Credit
Time to Complete: 1 hour
Released: January 21, 2025
Expires: January 21, 2026
Maximum Credits:
1.00 / ANCC Contact Hour
Learning Objectives:
- Explain the results of key clinical trials that demonstrate the efficacy and safety of new and emerging agents for the treatment of advanced PC.
- Devise strategies to optimize therapy for PC for individual patients in the community urology setting.
- Discuss the roles of nurses and advanced practice providers in improving PC management in the community urology setting.
Course Description:
This program provides healthcare professionals with the latest insights into advanced prostate cancer management to enhance patient care. It equips nurses and advanced practice providers with the tools to critically evaluate the efficacy, safety, and clinical application of new and emerging therapies. Participants will learn strategies for personalizing treatment using biomarkers and clinical factors, including intensification approaches for nonmetastatic and metastatic disease. The program also explores the roles of the healthcare team in improving patient outcomes in community urology settings. This will prepare participants to integrate evidence-based therapies and strategies into practice to improve survival and quality of life for prostate cancer patients.
Provided by PleXus Communications
Hybrid Community/VHA Oncology Forums: EGFR Exons 19 and 21 Alterations in Non-Small Cell Lung Cancer: Recent Therapeutic Advances and Implications for Care
CME | CNE | CPE | 1.00 Credit
Time to Complete: 1 hour
Released: January 22, 2025
Expires: January 22, 2026
Maximum Credits:
1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour
1.00 / CE for Pharmacists
Learning Objectives:
- Explain current testing types, strategies, and recommendations for molecular testing of patients with NSCLC and how they inform treatment decision-making for patients with EGFR alterations, particularly exon 19 and 21
- Survey recent trial data regarding the safety and efficacy data of targeted therapies and combinations for NSCLC patients with EGFR exon 19 and 21 alterations
- Outline optimal treatment plans in both the adjuvant and advanced settings for NSCLC patients with EGFR exon 19 and 21 alterations and approaches to effectively communicate treatment goals and considerations with patients
- Appraising strategies to identify and mitigate TRAEs associated with anti-EGFR targeted therapies within MDC teams
Course Description:
This program offers comprehensive education for oncology and lung cancer MDC teams on managing NSCLC with EGFR exon 19 and 21 alterations. It covers molecular testing strategies, recent trial data on targeted therapies, and optimal treatment plans in adjuvant and advanced settings. Participants will learn to communicate effectively with patients about treatment goals and address treatment-related adverse events (TRAEs). The curriculum emphasizes patient-centered care, interdisciplinary collaboration, and lifelong learning for improved outcomes. By addressing practice gaps, the program equips healthcare teams with essential tools for evidence-based decision-making and safer, more effective care.
Provided by PleXus Communications
PARP Inhibitors for Metastatic Prostate Cancer in the VHA Health System: Integrating New Agents into Practice
CME | CNE | CPE | 1.00 Credit
Time to Complete: 1 hour
Released: February 14, 2025
Expires: February 14, 2026
Maximum Credits:
1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour
1.00 / CE for Pharmacists
Learning Objectives:
- Analyze recent clinical trials and real-world evidence regarding poly-ADP ribose polymerase inhibitors (PARPi) monotherapy and PARPi combinations as therapy for metastatic prostate cancer (mPC).
- Summarize the current best practices for applying PARPi based on DNA repair alterations and other biomarkers.
- Formulate personalized PARPi-based therapeutic strategies to improve the survival of Veterans with mPC.
- Determine how PARPi safety profiles will influence mPC management for individual patients, based on their preferences, comorbidities, prior therapies, and other disease-related considerations.
Course Description:
This program equips clinicians with the knowledge to optimize care for patients with metastatic prostate cancer (mPC) by integrating PARP inhibitors into practice. It explores the latest evidence on genetic testing, biomarker-driven treatment selection, and personalized therapeutic strategies for mPC. Clinicians will learn about indications for PARP inhibitor monotherapy and combination therapies, alongside strategies to manage associated safety concerns. Through a review of recent clinical trials and real-world data, participants will gain insights into improving patient survival and quality of life. By the program's end, attendees will be prepared to apply evidence-based PARP inhibitor therapies.
Provided by PleXus Communications